Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NS Pharma, Inc.
With
Nippon Shinyaku Co., Ltd.
Age
4–14
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male ≥ 4 years and \<15 years of age
Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon 44 to restore the dystrophin mRNA reading frame
Able to walk independently without assistive devices
Ability to complete the TTSTAND without assistance in \<20 seconds
Stable dose of glucocorticoid for at least 3 months and the dose is expected to remain on a stable dose for the duration of the study.
You may not be if
Has a body weight of \<20 kg at the time of informed consent (applies to participants screening for Part 1 only)
Evidence of symptomatic cardiomyopathy
Current or previous treatment with anabolic steroids (e.g., oxandrolone) or products containing resveratrol or adenosine triphosphate within 3 months prior to first dose of study drug
Current or previous treatment with any other investigational drug within 3 months prior to the first dose of study drug or within 5 times the half-life of a medication, whichever is longer
Surgery within the 3 months prior to the first dose of study drug or planned during the study duration
Previously treated in an interventional study of NS-089/NCNP-02
Having received exon skipping oligonucleotide within 1 year prior to the first dose of IP
Clareo Health | NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
